Daewoong Pharmaceutical Confirms Efficacy and Safety in Phase 3 Clinical Trial of Diabetes Treatment
[Asia Economy Reporter Minwoo Lee] Daewoong Pharmaceutical announced on the 14th that it has confirmed the efficacy and safety of the Phase 3 clinical trial results for the type 2 diabetes treatment 'DWP16001 (SGLT2 inhibitor)' in both monotherapy and combination therapy. Accordingly, it plans to apply for new drug approval from the Ministry of Food and Drug Safety in the first half of this year. This is the first domestically developed new drug of an SGLT2 inhibitor in Korea.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- "Target Price Set at 970,000 Won"... Top Investors Already Watching, Only an 'Uptrend' Remains [Weekend Money]
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
